Home Abortion Tags

Abortion

"KFF graphic with white text on a purple background that reads "Interactive Dashboard: Abortion in the United States." The graphic also has photo illustrations of the Supreme Court and abortion medication."

The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →

View the Latest: Abortion

Filter

List Grid

91-100 of 298 results

  • The Latest on Medication Abortion Access: The Court Awaits the FDA Review

    Quick Insights

    Despite for calls from Republican leaders and anti-abortion organizations for the FDA to act quickly, the Louisiana district court has given the FDA until October 7, 2026, one month before the midterms, to file a report with the status of its review and any updated timeframe for completion. In the meantime, clinicians may continue to mail mifepristone to pregnant patients seeking abortions regardless of where they live.

  • Supreme Court Leaves Mifepristone Access Unchanged – For Now

    Quick Insights

    In addition to ongoing litigation, last September the Trump administration FDA, after  requests from anti-abortion organizations and state attorneys general, initiated an internal review of mifepristone’s safety.  This adds uncertainty as the agency could revise dispensing rules independently of the courts. With the FDA commissioner’s resignation this week and no permanent leader in place, the timeline for completing the review remains unclear. 

  • Abortions Later in Pregnancy in a Post-Dobbs Era

    Issue Brief

    This brief explains why individuals may seek abortions later in pregnancy, how often these procedures occur, and the various laws which regulate access to abortions later in pregnancy across the country.

  • Out-of-Pocket Costs for Long-Acting Reversible Contraception Among Individuals Enrolled in Employer Sponsored Insurance Plans

    Perspective

    In this analysis, published in the journal Contraception, KFF’s Linda Li, Brittni Frederiksen, and Alina Salganicoff look at intrauterine device (IUD) and contraceptive implant insertion-related costs among privately insured individuals to better understand why patients are experiencing unexpected expenses for what should be fully covered contraceptive services under the ACA.

  • KFF Health Tracking Poll: Knowledge and Views of Medication Abortion

    Poll Finding

    This KFF Health Tracking Poll finds that many, including women of reproductive age, remain unfamiliar with key facts about mifepristone. Fewer than half of all adults say they believe abortion pills are safe now, compared to over half of all adults two years ago. This poll explores awareness and perception of the recent FDA review of the medication, and support for policies aimed at restricting it.

  • Since Dobbs, Few Large Firms Have Changed Their Plan’s Abortion Coverage Policy

    News Release

    According to an analysis of responses to KFF’s Employer Health Benefits Survey in 2023, relatively few (8%) large firms (with 200 or more workers) offering health benefits report reducing or expanding coverage for abortion since the U.S. Supreme Court overturned Roe v. Wade with the Dobbs v. Jackson ruling. Since Dobbs, 3% of these large firms reduced or eliminated coverage for abortion where it is legal. Meanwhile, 12% of large firms whose largest plan covers…